MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)
Status:
Withdrawn
Trial end date:
2020-11-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability, and pharmacodynamics of
MK-5475 after administration of multiple doses to participants with COVID-19 pneumonia. The
primary hypothesis is that MK-5475 when administered to participants with COVID-19 pneumonia
and hypoxemia improves arterial oxygenation as measured by the ratio of blood oxygen
saturation to fraction of inspired oxygen (SpO2/FiO2 ratio) compared to placebo.